Key result
Milrinone dosing in HF lacks clear guidelines due to arrhythmia, hypotension, and renal clearance concerns.
This review highlights the lack of clear guidelines for milrinone dosing in end-stage heart failure and examines the balance between its hemodynamic benefits and adverse events.
No takes yet. Share an insight, caveat, or question.
Clinicians should individualize milrinone dosing amid safety concerns; leaves open optimal regimens for prospective HF trials.
Chong et al. (2017) conducted a review in End-stage heart failure and acute decompensated heart failure. Milrinone was evaluated. Milrinone dosing in heart failure lacks clear guidelines, with clinical practice often limited by concerns over arrhythmias, hypotension, and renal clearance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: